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Available online 18 November 2015Test batteries to screen chemicals for mutagenic hazard include several endpoints regarded as effective for de-
tecting genotoxic carcinogens. Traditional in vivo methods primarily examine clastogenic endpoints in
haematopoietic tissues. Although this approach is effective for identifying systemically distributed clastogens,
some mutagens may not induce clastogenic effects; moreover, genotoxic effects may be restricted to the site of
contact and/or related tissues. An OECD test guideline for transgenic rodent (TGR) genemutation assays was re-
leased in 2011, and the TGR assays permit assessment of mutagenicity in any tissue. This study assessed the re-
sponses of two genotoxicity endpoints following sub-chronic oral exposures of male Muta™Mouse to 9
carcinogenic polycyclic aromatic hydrocarbons (PAHs). Clastogenicity was assessed via induction of micronuclei
in peripheral blood, andmutagenicity via induction of lacZ transgenemutations in bonemarrow, glandular stom-
ach, small intestine, liver, and lung. Additionally, the presence of bulky PAH-DNA adducts was examined. Five of
the 9 PAHs elicited positive results across all endpoints in at least one tissue, and no PAHswere negative or equiv-
ocal across all endpoints. All PAHswere positive for lacZmutations in at least one tissue (sensitivity=100%), and
for 8 PAHs, one or more initial sites of chemical contact (i.e., glandular stomach, liver, small intestine) yielded a
greater response than bone marrow. Five PAHs were positive in the micronucleus assay (sensitivity = 56%).
Furthermore, all PAHs produced DNA adducts in at least one tissue. The results demonstrate the utility of the
TGR assay for mutagenicity assessment, especially for compounds that may not be systemically distributed.
Crown Copyright © 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Muta™Mouse1. Introduction
In 1973 Ames and colleagues published a scientiﬁc paper proclaiming
“Carcinogens are Mutagens” (Ames et al., 1973). Since then, a ﬂurry of
publications has debated the validity of this statement. Currently, the ge-
netic toxicology community acknowledges that 65 to 90% of rodent car-
cinogens will elicit a positive response in at least one of the standard
regulatory assays for genetic toxicity (Hernandez et al., 2009, Kirkland
et al., 2005, Waters et al., 2010, Zeiger, 1998).
Genetic toxicology test batteries are generally effective for detecting
carcinogenic compounds, and the sensitivity of the three-test battery is
quite high (i.e., 85–90%, depending on the assays included) (Kirkland
et al., 2005). However, not all chemicals ﬁt this paradigm, and there is
increasing recognition of response inconsistency. In vivo “false nega-
tives” are known rodent carcinogens that fail to induce a positive re-
sponse in an in vivo genotoxicity assay and may be the result of eitherTunney's Pasture, A/L 0803A,
).
r Inc. This is an open access article u(i) a lack of target tissue exposure, or (ii) endpoint incompatibility, or
potentially both. With respect to the former, the standard test battery
often examines haematopoietic tissue; however, the target tissue for
mutation or chromosome damage may be a solid organ such as the
liver or the gastrointestinal tract. With respect to the latter, in vitro
tests may assess the induction of mutations, whereas the in vivo tests
often assess clastogenicity. Yet, mutagenic compounds do not necessar-
ily induce chromosome damage, and examining only clastogenicity
in vivomay result in amissed positive response induced by amutagenic
carcinogen. By examining mutagenicity both in vitro and in vivo, it may
be possible to resolve some in vivo false negatives.
Researchers have attempted to resolve problems related to a lack of
target tissue exposure by designing assays that assess genotoxicity in
the tissue that is suspected to be a target for induced genetic damage
or carcinogenesis. Examples include unscheduled DNA synthesis in
liver (OECD, 1997b), the comet assay for DNA strand breaks in various
target tissues (Collins, 2004, JaCVAM, 2012, OECD, 2013, Rothfuss
et al., 2010), and the liver micronucleus (MN) assay (Suzuki et al.,
2004, Suzuki et al., 2005, Suzuki et al., 2009, Takasawa et al., 2010,
Takasawa et al., 2013). Several in vivomammalian genemutation assaysnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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are labour intensive, require large numbers of animals, and are prohib-
itively costly (e.g., the in vivo Hprtmutation assay). A novel endogenous
gene mutation assay based on the Pig-a gene was more recently devel-
oped (Bryce et al., 2008); however, it is also currently restricted to
haematopoietic tissue, and will require validation before it can be
adopted for routine use.
Tests for gene mutations in TGRs (transgenic rodents) may be capa-
ble of resolving the issues leading to false negative results since they can
detect induced transgene mutations in vivo in almost any target tissues.
An OECD test guideline for the TGR somatic and germ cell gene muta-
tion assay (OECD test guideline #488) was approved on July 28, 2011
(OECD, 2011). The Muta™Mouse TGR assay has been tested with a
wide range of knownmutagens, and it has accurately returned positive
results in several target tissues (for a review, see Lambert et al., 2005 &
Lambert et al., 2009). Additionally, it can be combinedwith other assays
that detect cytogenetic damage, such as the peripheral blood MN assay
(OECD, 1997a). This is advantageous, as it is difﬁcult to combine the
comet assay, which can also provide tissue-speciﬁc indications of DNA
damage, with other genotoxicity endpoints (e.g., TGR mutations, MN,
or Pig-amutations) as the timing of sample collection for comet cannot
be accommodated in the OECD test guidelines or recommended proto-
cols for the other endpoints (OECD, 2013). A previous study published
by our group simultaneously examined the frequency of transgene
(lacZ) mutations, Pig-a mutations, and MN induced in Muta™Mouse
by oral exposure to benzo(a)pyrene (BaP), a prototypical polycyclic ar-
omatic hydrocarbon (PAH) (Lemieux et al., 2011).
PAHs are a ubiquitous group of combustion-derived organic com-
pounds containing at least two fused benzene rings. Several PAHs, par-
ticularly the larger ﬁve- and six-ring compounds, are mutagens in
mammals and other vertebrates, and are classiﬁed by the International
Agency for Research on Cancer (IARC) as carcinogens (IARC, 1983, IARC,
2010). IARC currently lists one PAH (i.e., BaP) as a known human carcin-
ogen (Group 1), three PAHs as probable human carcinogens (Group
2A), and eleven PAHs as possible human carcinogens (Group 2B)
(IARC, 1983, IARC, 2010).
PAHsmust bemetabolically transformed to becomeDNA reactive. The
majormutagenic pathway of PAHactivation is via the production of DNA-
reactive dihydrodiol-epoxides via CYP1 isozymes and epoxide hydrolase.
The PAH-dihydrodiol-epoxides exert their mutagenic effect by covalently
binding to a nucleotide, thereby forming a bulky DNA adduct. If these ad-
ducts aremis-repaired they can cause permanent DNA sequence changes
(i.e., mutations); mutations in critical genes can lead to uncontrolled cell
proliferation and replicative immortality, eventually leading to the estab-
lishment of neoplasia (Cairns, 1998, Josephy, 1997).
Cytochrome P450 1a1 (CYP1A1) is the major enzyme responsible for
catalysing the initial oxidation of PAHs; however, other P450 isozymes
such as CYP1B1 and CYP1A2 are also capable of catalysing oxidative reac-
tions (Shimada et al., 2002, Shimada and Fujii-Kuriyama, 2004, Xue and
Warshawsky, 2005). CYP1A2 is a major hepatic P450 isozyme, whereas
CYP1A1 and 1B1 are primarily expressed extra-hepatically in several
murine tissues including lung and small intestine (Choudhary et al.,
2003, Hart et al., 2009, Renaud et al., 2011, Zhang et al., 2003). CYP1A1
is generally present only at low levels unless its expression is induced
via aryl hydrocarbon receptor (AhR) agonism,whereas CYP1B1 is consti-
tutively expressed in certain tissues, and a substantial amount of CYP1A2
activity is present in liver. Both of these enzymes can also be upregulated
following induction via AhR agonism (Nebert et al., 2004).
A second PAH-activation pathway, known as the radical cation path-
way, involves one-electron oxidation that produces PAH radical cations
that contribute to the formation of depurinating adducts. A third activa-
tion pathway involves the PAH-dihydrodiol intermediate produced by
CYP1 metabolism and further metabolism by aldo-keto reductases
(AKRs) to produce a catechol that can undergo oxidation to generate
o-quinones. The resulting o-quinones can form covalent DNA adducts
or undergo redox cycling that generates oxidative DNA damage. Thisthird pathway is known as the o-quinone or AKR pathway (Penning,
2014).
To expedite assessments of PAH-contaminated matrices
(e.g., contaminated soil, urban air particulates) regulatory agencies
have identiﬁed a select number of PAHs that are routinely the focus of
concern and control (i.e., the US EPA 16 priority PAHs). The United
States Environmental Protection Agency (US EPA) designates seven
priority PAHs as B2 carcinogens (i.e., probable human carcinogens)
(Keith and Telliard, 1979). The Canadian Environmental Protection Act
(CEPA) identiﬁes ﬁve PAHs as probable human carcinogens (CEPA,
1994). Few studies have examined the in vivo genotoxic potency of
the aforementioned B2 carcinogens; an assessment of their relative po-
tency across a number of tissues would permit an evaluation of existing
in vivo endpoints for genotoxicity assessment, and the identiﬁcation of
critical tissues for effective hazard identiﬁcation and assessment.
The objectives of this study were to evaluate the ability of the
Muta™Mouse TGR lacZmutation assay to correctly return a positive re-
sult in various tissues for selected carcinogenic PAHs, and to compare
the sensitivity of the TGR response to another regulatory genotoxicity
endpoint (i.e., peripheral blood MN assay). Nine genotoxic PAHs were
selected for this study (Table 1); they are either listed as IARC Group 1
and 2 carcinogens, are US EPA B2 carcinogens, or were previously
found to be genotoxic in Muta™Mouse FE1 cells (IARC, 2010, Keith
and Telliard, 1979, Lemieux et al., 2015). BghiP is classiﬁed as Group 3
by IARCdue to inadequate evidence to evaluate its carcinogenicity in ex-
perimental animals; however numerous studies have shown that BghiP
can induce the formation of stable adducts (IARC, 2010), and it elicits a
positive mutation response in Muta™Mouse FE1 cells. Therefore, it was
also included in the current study. The PAHs examined herein are
benz(a)anthracene (BaA; IARC Group 2B), dibenz(a,h)anthracene
(DBahA; IARC Group 2A), benzo(b)ﬂuoranthene (BbF; IARC Group
2B), chrysene (CHRY; IARC Group 2B), benzo(k)ﬂuoranthene (BkF;
IARC Group 2B), indeno(1,2,3-c,d)pyrene (INDENO, IARC Group 2B),
and DBalP (IARC Group 2A; also known as dibenzo(def,p)chrysene),
and BghiP (IARC Group 3). The previously published results for BaP
(IARC Group 1) (Labib et al., 2012, Lemieux et al., 2011), the liver lacZ
mutation and DNA adduct data for DBahA (Malik et al., 2013), as well
as lung lacZ mutation and DNA adduct data recently published by
Labib et al. (2015) (for all compounds except DBalP) are also included
in our analyses.
2. Materials & methods
2.1. Animal treatment
Adult male Muta™Mouse (strain 40.6) specimens were individually
housed in a microVENT ventilated rack (Allentown Inc., Allentown, NJ)
on a 12-h light/12-h dark cycle. Animals received standard rodent
chow (2014 Teklad Global standard rodent diet) and water ad libitum
for the duration of the study. Animals were administered BaP, BaA
(Sigma-Aldrich, Oakville, ON, Canada), DBahA, BbF, CHRY, BkF,
INDENO, BghiP, and DbalP (Cambridge Isotopes, Tewksbury, MA) dis-
solved in highly reﬁned olive oil (Sigma-Aldrich), and administered at
0.005 ml/g body weight. Compound purity, Chemical Abstract Service
(CAS) numbers, doses and animal ages at the commencement of each
study, as well as data source (i.e., from this study or previously
published) are listed in Table 1. The doses were administered daily by
oral gavage for 28 consecutive days. Doses were selected based on
preliminary range-ﬁnding experiments for each compound, and the
selected doses did not elicit overt signs of toxicity. There were ﬁve ani-
mals in each dose group and the vehicle control group. As per OECD
guideline#474, 2-days following the last dose (i.e., one day prior to nec-
ropsy), all animals were bled via the saphenous or facial vein in order to
obtain peripheral blood for the MN assay (OECD, 1997a). All animals
were euthanized at 3 days post-dosing (OECD, 2011) via cardiac punc-
ture under isoﬂurane anaesthesia, followed by cervical dislocation and
Table 1
Description of chemicals, doses, animal ages at the commencement of exposures, and data sources for the analyses presented in this work.
Compound CAS # Purity Dose (mg/kg BW/day) Animal age Data source
Low Med High
BaP 50–32-8 99% 25 50 75 25 weeks Lemieux et al., 2011, Labib et al., 2012
BaA 53–55-3 99% 20 40 80 10 weeks This studya
DBahA 53–70-3 ≥98% 6.25 12.5 25 10 weeks Malik et al., 2013 (lacZ and DA in Lv), this studya
BbF 205–99-2 ≥98% 25 50 100 16 weeks This studya
CHRY 218–01-9 ≥98% 20 40 80 14 weeks This studya
BkF 207–08-9 ≥98% 25 50 100 11 weeks This studya
INDENO 193–39-5 ≥98% 12.5 25 50 13 weeks This studya
BghiP 191–24-2 ≥98% 6.25 12.5 25 10 weeks This studya
DBalP 191–30-0 ≥98% 0.2 0.6 2 12 weeks This study
DA: DNA adducts; Lv: liver.
a Mutation and DA data for lung only published in Labib et al. (2015).
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was ﬂushed out, pelleted via brief centrifugation, and ﬂash frozen in
liquid nitrogen. The small intestine and glandular stomachwere ﬂushed
with PBS and ﬂash-frozen. The liver and lung were removed and ﬂash
frozen. All tissues were stored at−80 °C. Mice were bred, maintained,
and treated in accordance with the Canadian Council for Animal Care
Guidelines, and the protocolswere approved byHealth Canada's Animal
Care Committee.2.2. Genomic DNA isolation for lacZ mutation scoring and PAH-DNA adduct
analysis
Murine tissueswere prepared for total genomic DNA isolation in the
following manner:
Bone marrow: Thawed bone marrow was combined with 5-ml ice
cold lysis buffer (1 mM Na2EDTA, 100 mM NaCl, 20 mM Tris–HCl,
pH 7.4, 1% SDS (w/v)) and incubated overnight at 37 °C with gentle
shaking.
Liver: The right lobe of the liver was thawed and homogenized in
TMST (50 mM Tris, pH 7.6, 3 mMmagnesium acetate, 250 mM sucrose,
0.2% Triton X-100) using a Dounce tissue grinder. The homogenized tis-
sue was then pelleted by centrifugation for 6 min at 800 ×g (4 °C) and
washed twice in TMST. The pellet was then re-suspended in 5 ml lysis
buffer and incubated overnight at 37 °C with gentle shaking.
Small intestine: Tissue from the jejenum was slit open and the
mucus layer and intestinal contents were removed by rinsing the tissue
in ice-cold buffer (75 mM KCl, 20 mM EDTA) via repeated aspiration
(i.e., 3–4 times) in and out of a 1-ml needleless syringe. The epithelial
lining was then removed from the supporting tissue by repeatedly
(10 times) forcing the tissue in and out of the syringe in fresh buffer.
The sample was then centrifuged for 10 min at 2800 rpm (4 °C), re-
suspended in 5 ml lysis buffer, and incubated overnight at 37 °C with
gentle shaking.
Lung: Lung tissue (right lobe) was minced and placed in a sterile
tube containing PBS. The tissue was then de-gassed by applying a
vacuum to the top of the tube. The tubes were then centrifuged and
re-suspended in 5 ml lysis buffer for an overnight incubation at 37 °C
with gentle shaking.
Glandular stomach: Stomach tissue was opened and ﬂushed with
PBS, and then scraped using the edge of a scalpel blade. The scraped tis-
sue was transferred to a glass Dounce tissue grinder and homogenized.
The homogenized tissue was combined with 5 ml lysis buffer and incu-
bated for 1 h at 37 °C with gentle shaking. RNAse A (0.1 mg/ml) was
then added and samples incubated overnight at 37 °C with gentle
shaking.
Genomic DNA was isolated from all lysed tissues using a phenol/
chloroform extraction procedure described previously (Douglas et al.,
1994, Vijg and Douglas, 1996). Isolated DNA was dissolved in 100 μl
TE buffer (10 mM Tris pH 7.6, 1 mM EDTA) and stored at 4 °C until use.2.3. Mutant frequency analysis
ThePGal (phenyl-β-D-galactoside) positive selection assaywasused
for the determination of lacZ mutant frequency in DNA samples from
bonemarrow, liver, lung, glandular stomach, and small intestine, as pre-
viously described (Gossen et al., 1992, Lambert et al., 2005, Vijg and
Douglas, 1996). Mutant frequency was calculated as the ratio of mutant
plaque forming units (pfu) to total pfu.
2.4. PAH-DNA adduct analysis
The nuclease P1 enrichment version of the 32P-postlabelling assay
was used to determine DNA adduct frequency in DNA samples from
bone marrow, liver, lung, glandular stomach, and small intestine. The
procedure was performed as described in Phillips and Arlt (2014) and
Arlt et al. (2008), withmodiﬁcations as described in Malik et al. (2013).
2.5. Micronucleus assay
MicroFlow® kits (Litron Laboratories, Rochester, NY) were used for
enumeration of micronucleated reticulocytes (RET) and normochromatic
erythrocytes (NCE). Brieﬂy, approximately 60 μl of peripheral blood was
immediately combined with 350 μl of anticoagulant. Blood samples
were then ﬁxed by transferring to ice-cold methanol and stored at−80
°C. After 3–5 days, ﬁxed blood samples were then centrifuged, rinsed,
and transferred to a long-term storage solution. Coded specimens were
shipped to Litron Laboratories (Rochester, NY) for analysis. Micronuclei
were scored in NCEs (i.e., MN-NCEs) and RETs (i.e., MN-RETs) by ﬂow cy-
tometry via a 3-colour labelling method described in (Dertinger et al.,
2004, Torous et al., 2001).
2.6. Data analysis
The lacZ and MN dose–response data were analysed in SAS v.9.1
(SAS Institute, Cary, NC) using Poisson regression. The data were ﬁt to
the model log(E(Yi)) = log ti + βxi, where E(Yi) is the expected value
for the ith observation, β is the vector of regressions coefﬁcients, xi is a
vector of covariates for the ith observation, and ti is the offset variable
used to account for differences in observation count period (e.g., total
pfu). The offset (e.g., natural log of pfu) was given a constant coefﬁcient
of 1.0 for each observation, and log-linear relationships betweenmutant
count and test article concentration were speciﬁed by a natural log link
function.
Genotoxic potencieswere calculated for each endpoint in each tissue
as the slope of the linear portion of the dose–response functions. BaP
MN (in blood), as well as DNA adducts and lacZ data in bone marrow,
liver, small intestine and glandular stomach were previously published
in Lemieux et al. (2011). Lung data were previously published in Labib
et al. (2012). DBahA lacZ mutant frequency data for liver only were
Table 3
Genotoxic response for lacZmutagenicity results in glandular stomach (GS), small intes-
tine (SI), liver, (Lv), lung (Lg), and bone marrow (BM), and micronucleus (MN) results
in reticulocytes (RETs) and normochromatic erythrocytes (NCEs). Sensitivity for each tis-
sue is also presented.
Compound
lacZ MN
GS SI Lv Lg BM RETs NCEs
BaP +++ +++ +++ +++ +++ + ++
BaA + + WP − + − −
DBahA + +++ + +++ − + +
BbF +++ +++ +++ ++ ++ + +
CHRY − + − WP − − −
BkF + ++ + + + + +
INDENO + +++ + + + − −
BghiP − + − + − − −
DBalP ++ + ++ + +++ ++ +
Total Pos 7 9 7 8 6 5 5
Total Neg 2 0 2 1 3 4 4
Sensitivity 78% 100% 78% 89% 67% 56% 56%
+: Dose–response, 1.5–5-fold above background; ++: Dose–response, 5–10-fold above
background; +++: Dose–response, N10-fold above background; WP (weak positive):
dose–response, but below 1.5-fold above background;−: Negative.
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adduct data for BaA, DBahA, BbF, CHRY, BkF, INDENO, and BghiP were
recently published in Labib et al. (2015). These data were re-analysed
in the manner stated above to permit direct comparison to the results
generated speciﬁcally for this study.
3. Results
3.1. DNA adducts
For simplicity, the DNA adduct data were only qualitatively exam-
ined (i.e., positive or negative) to investigate target tissue exposure to
reactive metabolites (Table 2). The adduct data will be analysed and
discussed in more detail (i.e., quantitative analyses) in a separate man-
uscript. Six of the 9 PAHs (i.e., BaP, BaA, DBahA, BbF, BkF, and DBalP) in-
duced signiﬁcant increases in DNA adduct frequencies in all 5 tissues
examined (i.e., glandular stomach, small intestine, liver, lung, bonemar-
row). CHRY elicited a positive response in all tissues except bone mar-
row. INDENO only elicited a positive response in liver and lung. BghiP
only elicited a positive response in lung. Interestingly, lung was the
only tissue to show a signiﬁcant response for all 9 PAHs.
3.2. lacZ mutagenicity
The Muta™Mouse TGR assay was able to correctly identify the se-
lected PAHs as in vivo mutagens, and all 9 PAHs elicited positive re-
sponses in at least one tissue (Table 3). BaP, BbF, BkF, INDENO, and
DBalP elicited signiﬁcant increases in lacZmutant frequency in all 5 tis-
sues examined (Table 3; Fig. 1A, D, F, G, I). BaA andDBahA elicited a pos-
itive response for 4 out of the 5 tissues, with negative responses for lung
and bone marrow, respectively (Table 3; Fig. 1B, C). CHRY and BghiP
elicited positive responses in only 2 of the 5 tissues examined, both
were negative in glandular stomach, liver, and bone marrow (Table 3;
Fig. 1E, H). For all PAHs examined, with the exception of DBalP, the
fold-increase in mutant frequency (i.e., over control) for site of contact
or related tissues (i.e., small intestine, glandular stomach, liver) was
higher than for bone marrow (Fig. 1). The largest fold-increase in mu-
tant frequency for BaP, DBahA, BbF, CHRY, BkF, and INDENO was ob-
served for small intestine (Fig. 1A, C, D, E, F, G). For BaA, only
glandular stomach yielded a larger fold-change than small intestine
(Fig. 1B), and for BghiP, only lung yielded a larger fold-change than
small intestine (Fig. 1H). For DBalP, the largest fold-change over control
was obtained for bone marrow (Fig. 1I). For BbF, BkF, and INDENO (Fig.
1D, F, G), bone marrow results showed the smallest fold-change over
control, and for DBahA, CHRY, and BghiP, the bone marrow responses
were negative (i.e., no signiﬁcant increase) (Fig. 1C, E, H).
3.3. Micronucleus (MN) frequency
BaP, DBahA, BbF, BkF, and DBalP elicited statistically signiﬁcant pos-
itive results in theMNassay for both RETs andNCEs (Table 3, Fig. 2A–E).
BaA, CHRY, INDENO, and BghiP did not elicit signiﬁcant positive re-
sponses for the MN assay (Table 3). Larger fold-changes over controlTable 2
PAH-DNA adduct result across all 5 tissues for each PAH examined.
Compound Glandular stomach Small intestine Liver Lung Bone marrow
BaP + + + + +
BaA + + + + +
DBahA + + + + +
BbF + + + + +
CHRY + + + + −
BkF + + + + +
INDENO − − + + −
BghiP − − − + −
DBalP + + + + +were consistently seen in RETs, versus NCEs, with the sole exception
being BaP (Fig. 2A). This highlights the importance of scoring
micronuclei in the immature red blood cell population (i.e., RETs),
which captures the effects of recent damage.
CHRY, BaA, and INDENO are all IARC Group 2B carcinogens forwhich
experimentally-induced genetic damage is well documented; however,
the results obtained herein indicate an inability of these compounds to
induceMN. This is noteworthy and concerning since the results support
the contention that theMN assay in peripheral blood,which is routinely
employed for regulatory screening, has a limited ability to detect PAH-
induced genetic damage.
3.4. Potency comparisons
The potency (i.e., slope of the linear portion of the dose–response
function) of each compound was ranked by tissue for each endpoint
(i.e., 1=most potent, 5= least potent) (Table 4). For the lacZmutation
endpoint, the highest potency (i.e., rank=1) was observed in small in-
testine for 6 out of 9 PAHs (i.e., BaP, DBahA, BbF, CHRY, BkF, INDENO).
Potencies for small intestine were second highest (i.e., rank = 2) for
the remaining 3 compounds (i.e., BaA, BghiP, DBalP). Conversely, 3 com-
pounds failed to elicit a positive response in bone marrow (i.e., DBahA,
CHRY and BghiP), and bone marrow responses were least potent
(i.e., rank = 5) for an additional 3 compounds (i.e., BbF, BkF, INDENO).
Interestingly, DBalP elicited themost potent response (i.e., rank= 1) in
bone marrow. Effects on glandular stomach and lung showed interme-
diate potency for all compounds, with potency ranks ranging from 1 to
5, whereas responses in the liver were the least potent after bone mar-
row, with potency ranks ranging from 2 to 4. A mean relative potency
score was calculated for each tissue, across all compounds, in order to
provide a general potency ranking for PAHs in the tissues examined.
Themost potent response was observed in small intestine (1.3), follow-
ed by glandular stomach (2.9), lung (3.0), liver (3.3), and ﬁnally bone
marrow (3.7).
For the MN endpoint, the most potent responses were observed in
RETs for all compounds that yielded a signiﬁcant positive response
(i.e., DBahA, BbF, BkF, DBalP), with the sole exception of BaP (Fig. 2).
BaP yielded a more potent response in NCEs (Fig. 2), resulting in mean
potencies of 1.2 for RETs, and 1.8 for NCEs.
3.5. Cross-tissue comparisons
For theMuta™Mouse lacZmutation endpoint BaP elicited the largest
fold-change increase over control across all 5 tissues, which is not sur-
prising since BaP is known to be a potent mutagen and carcinogen
Fig. 1. Muta™Mouse lacZ mutagenicity results for 9 PAHs in bone marrow (BM), liver (Lv), glandular stomach (GS), small intestine (SI), and lung (Lg). Plots show results for
(A) benzo(a)pyrene, (B) benz(a)anthracene, (C) dibenz(a,h)anthracene, (D) benzo(b)ﬂuoranthene, (E) chrysene, (F) benzo(k)ﬂuoranthene, (G) indeno(1,2,3-c,d)pyrene,
(H) benzo(g,h,i)perylene, and (I) dibenzo(a,l)pyrene. Mutant frequencies± standard error are displayed for each tissue and dose. Statistical results for the overall dose–response relation-
ship are presented for each tissue. Results of the custom contrasts for each dose vs. control are markedwith an *, indicating signiﬁcance at p b 0.05. Ŧ: dose–response data were truncated
prior to X2 analysis. NS indicates not signiﬁcant.
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Fig. 2.Micronucleus (MN) frequency results for the 5 PAHs that elicited positive responses in this assay in reticulocytes (RETs) and normochromatic erythrocytes (NCEs). Plots show
results for (A) benzo(a)pyrene, (B) dibenz(a,h)anthracene, (C) benzo(b)ﬂuoranthene, (D) benzo(k)ﬂuoranthene, and (E) dibenzo(a,l)pyrene. Percent micronucleated blood cells
(i.e., % MN)± standard error are displayed for each tissue and dose. Statistical results for the overall dose–response relationship are presented for both tissues. Results of the custom con-
trasts for each dose vs. control are marked with an *, indicating signiﬁcance at p b 0.05.
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Unlike most other PAHs, BaP induced a potent lacZ response in bone
marrow. DBalP also elicited a positive lacZ mutagenicity response inTable 4
Relative ranking of lacZmutagenic potency for each compound in glandular stomach (GS),
small intestine (SI), liver, (Lv), lung (Lg), and bonemarrow (BM), as well as micronucleus
(MN) induction response in reticulocytes (RETs) and normochromatic erythrocytes
(NCEs). The last row shows mean rank across all compounds for a given tissue/endpoint.
Potencies are ranked 1–5. 1: highest potency for each compound per assay. 5: lowest
potency for each compound per assay. –: negative response.all tissues. Again, this is not surprising since DBalP is an extremely po-
tent in vivo mutagen. It is noteworthy that, in contrast to the results
for the other tested PAHs, the most potent response for this compound
was observed in bone marrow. This suggests that there is substantial
systemic distribution of DBalP, which is then metabolically converted
in bone marrow to a reactive metabolite (e.g., DBalP-11,12-diol-13,14-
epoxide). In comparison with BaP, DBalP elicited a smaller fold-change
increase for most tissues; however, due to the extreme toxicity of
DBalP (i.e., as observed in preliminary range-ﬁnding experiments), it
was necessary to select doses that are far lower than those used for
BaP (i.e., highest responses for DBalP observed at doses almost 40-fold
lower than BaP).
The fact that DBahA elicited a positive response in all tissues except
bone marrow is concerning since regulatory assessments often only ex-
amine haematopoietic tissue. It seems reasonable to assert that reactive
DBahA metabolites do not reach the bone marrow, and therefore are
unable to induce mutations in this tissue. However, DBahA did elicit
positive responses for theMN endpoint in RETs andNCEs, therefore sys-
temic exposure of reactive metabolites is likely. Indeed, systemic expo-
sure of the reactive metabolite was conﬁrmed by quantiﬁcation of
DBahA-induced bulky adducts in bone marrow at all three doses. The
fact that stable, bulky adducts do not appear to have been converted
to stablemutations in a rapidly proliferating tissue such as bonemarrow
may be an indication that there is sufﬁcient capacity for repair of DNA
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sponse for DBahA may have been induced by secondary metabolites,
such as reactive oxygen species, that did not contribute to the formation
of mutations in the bone marrow.
CHRY is a relatively weak carcinogen, causing lung and liver cancer
in mice following intraperitoneal (i.p.) administration, and lung cancer
in rats following intrapulmonary administration (IARC, 2010). IARC re-
cently declared CHRY a Group 2B carcinogen (i.e., possibly carcinogenic
to humans), which constitutes an upgrade from the earlier Group 3 dec-
laration. In our study, CHRY only elicited a clear positive response in
small intestine and a weak positive response in lung (i.e., signiﬁcant
dose response, but response at high dose below 1.5-fold above control).
The lacZmutation assay results suggest that lung was exposed to reac-
tive CHRY metabolites; indeed CHRY-DNA adducts were detected in
lung. In comparison, a lack of lacZ and MN responses in bone marrow
and peripheral blood, respectively, suggest that haematopoietic tissue
was not exposed. This was conﬁrmed by a lack of CHRY-induced DNA
adducts in bone marrow.
BkF and BbF, which are both IARC Group 2B carcinogens, elicited
positive responses across all tissues, with the greatest lacZmutant fre-
quency induction occurring in the small intestine. Both BbF and BkF in-
duced a positive response in the MN assay.
INDENO elicited positive lacZmutagenicity responses across all tis-
sues (i.e., including bone marrow), but failed to induce positive MN re-
sponses in RETs or NCEs, nor did the results revealmeasureable adducts
in bone marrow. Given the lack of bulky adducts in bone marrow, it is
unlikely that INDENO is being metabolized via the diol-epoxide path-
way in this tissue. Alternatively, the positive bone marrow response
may result from oxidative DNA damage produced via the o-quinone ac-
tivation pathway.
BaA,which is also classiﬁed as an IARCGroup 2B carcinogen, induced
a signiﬁcant positive response in the lacZmutagenicity assay in all tis-
sues except lung. The compound elicited a weak positive response in
the liver.
BghiP, which is classiﬁed by IARC asGroup 3 (i.e., not classiﬁable due
to limited or inadequate data in humans and experimental animals),
elicited a positive response in small intestine and lung. Similar to the re-
sults obtained for DBahA, the lack of positive response in bone marrow
is problematic from a regulatory point of view since assessments are
most commonly based on results for haematopoietic tissue. BghiP also
failed to elicit a positive MN response in both RETs and NCEs; therefore,
it is possible that there is no systemic distribution of activated metabo-
lites. Indeed, DNA adducts were not detected in the bone marrow of
BghiP-exposed animals. However, since a positive lacZ responsewas ob-
served in the lung, activatedmetabolites are either reaching the lung via
pulmonary circulation, or BghiP is being metabolically activated in the
lung itself.
3.6. Assay sensitivity
Table 3 summarizes the tissue-speciﬁc responses of the PAHs exam-
ined herein, and the response patterns therein are brieﬂy outlined
below. Importantly, the Muta™Mouse lacZ mutation assay was more
sensitive for all tested tissues (i.e., correct identiﬁcation of a genotoxic
carcinogen) in comparison with the MN assay in either RETs or NCEs
(Table 3). All of the PAHs investigated in this study elicited signiﬁcant
positive responses in the Muta™Mouse lacZmutation assay in at least
one tissue.
For the lacZmutagenicity assay, small intestine was the most sensi-
tive tissue, with a positive response for all 9 PAHs tested (100%)
(Table 3). Small intestine is a site-of-contact tissue for an oral exposure,
which may contribute to its high sensitivity for this assay. Lung, a re-
mote tissue for which responses were consistently lower in comparison
to site of contact, was the secondmost sensitive tissue (i.e., 89%). Lung is
the only common tumour site for all 9 PAHs, and therefore is a
toxicologically-relevant tissue for an oral exposure. The only compoundthat did not elicit a positive response in lung was BaA. Seven of the 9
PAHs examined elicited positive responses in both glandular stomach
and liver (78%). CHRY and BghiP were both negative in these tissues,
and also negative in bonemarrow. In the context of this study the glan-
dular stomach constitutes the site of ﬁrst contact, with compounds
interacting with stomach epithelium prior to contact with the small in-
testine or liver. It is reasonable to assert that the enzymatic activity and/
or residence time in the stomach may not be sufﬁcient to achieve ade-
quate conversion of the compounds into DNA-reactive metabolites
that elicit bulky adducts and transgene mutations. Bone marrow was
the least sensitive tissue for induction of lacZmutations, with only 6 of
9 compounds eliciting signiﬁcant positive responses; DBahA, CHRY,
and BghiP were all negative. As already noted, lack of responses for
knownmutagenic carcinogens are potentially a result of ineffective tar-
get tissue exposure to the reactive metabolite.
The sensitivity of the MN assay was equal for RETs and NCEs; with
both endpoints returning a positive response for 5 out of the 9 PAHs ex-
amined (56%).
From a regulatory evaluation point of view it is interesting to consid-
er the results as though the study only examined haematopoietic tissues
(i.e., bone marrow, blood), which would be the case if the MN assay
alone was employed. The results would have suggested that CHRY and
BghiP are not in vivo genotoxicants, despite the fact that both of these
compounds induced signiﬁcant positive responses in other Muta™-
Mouse tissues. If the study had examined the Muta™Mouse TGR end-
point in bone marrow only, we would have also missed the positive
response for DBahA, an IARC Group 2A carcinogen that elicited signiﬁ-
cant positive responses in all other tissues examined and response in-
duction levels more than 75- and 12-fold above control for small
intestine and lung, respectively. Finally, if we had only examined in-
duced increases in MN frequency in peripheral blood (i.e., RETs and
NCEs), we would have missed signiﬁcant positive responses for BaA,
INDENO, CHRY, and BghiP. BaA and INDENO elicited positive lacZmuta-
genicity responses in several tissues, including bone marrow. The fact
that these compounds are unable to elicit reliable positive responses
in haematopoietic tissues raises a concern regarding their ability to be
detected using standard regulatory assays for genetic toxicity, and high-
lights the importance of examining site-of-contact tissues and known
sites of tumour formation, either alone or in combination with
haematopoietic tissues.
4. Discussion
This study employed the Muta™Mouse TGR system to examine the
in vivo genetic toxicity of 9 PAHs. The compounds are all mutagenic car-
cinogens in animal models, and, with the exception of BghiP, are IARC
Group 1, 2A, or 2B human carcinogens. It is well-known that the
primary mode of action underlying PAH-induced carcinogenicity is
genotoxicity, and key events leading to the adverse outcome
(i.e., tumours) include the conversion of stable adducts to point muta-
tions or small insertions/deletions (IARC, 2010). Indeed, all 9 PAHs elic-
ited signiﬁcant positive responses in at least one tissue in the
Muta™Mouse lacZmutation assay, with 5 out of the 9 PAHs eliciting a
positive response in all 5 tissues, thereby demonstrating not only their
mutagenic potential, but also the ability of this assay to correctly identi-
fy genotoxic carcinogens.
Several PAHs have also been shown to inducemicronuclei as a result
of clastogenicity (Abramsson Zetterberg et al., 2013, Crofton Sleigh et al.,
1993, Glatt et al., 1990, He and Baker, 1991, Nishikawa et al., 2005,
Schober et al., 2006, Warshawsky et al., 1995, Whong et al., 1994).
Interestingly, only 5 of the 9 PAHs examined here elicited signiﬁcant
positive responses in the MN assay, indicating that a complementary
assay to detect in vivomutagenic activity is necessary to prevent “false
negatives”.
TheMN results in RETs consistently elicited larger fold-changes over
control, aswell as greater potency values in comparisonwith the results
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life span is only 1–2 days prior to their maturation into NCEs. Thus, by
examining RETs we are able to see evidence of the most recent damage
(Clark and Korst, 1969). As theymature, themutant RETs begin to accu-
mulate as mutant NCEs, which have a life span of 38–46 days in mice
(Horky et al., 1978). Therefore, the lower response in NCEs is likely to
be due to dilution; in other words, whereas all RETs were recently ex-
posed, only a subset of the sampled NCEs were exposed during the
28-day treatment period. Since affected cells accumulate, a longer sam-
pling time (i.e., N2 days post-exposure) would have increased themag-
nitude of the MN frequency response for NCEs (i.e., relative to RETs).
In this study BaP, DBalP, BbF, and BkFwere positive across all tissues
for both endpoints. A number of positive results for BaP-exposed TGRs
have been previously reported for several tissues including small intes-
tine, lung, liver, bone marrow, and spleen in Big Blue® mouse and rat,
Muta™Mouse, gpt delta mouse, Dlb-1 congenic mice, and the lacZ plas-
mid mouse (Boerrigter, 1999, Brooks et al., 1999, Delker et al., 2008,
Horibata et al., 2013, Leavitt, 2008, Monroe et al., 1998, Shane et al.,
1997, Skopek et al., 1996). BaP has previously been shown to induce
positiveMNresults in several tissues/cell types including skin, peripher-
al blood erythrocytes, and bone marrow (Abramsson Zetterberg et al.,
2013, Lemieux et al., 2011, Nishikawa et al., 2005). DBalP has previously
been tested in TGR assays, and a signiﬁcant increase in lacImutant fre-
quency was reported in Big Blue® mouse lung following an i.p. admin-
istration (Leavitt, 2008), as well as a signiﬁcant increase in cII mutant
frequency in Big Blue® mouse tongue, following a topical application
in the oral cavity (Chen et al., 2013). Our group recently published pos-
itive DNA adduct and lacZ results in spleen and bonemarrow, as well as
positiveMN results in peripheral blood, following a 3-day oral exposure
(Chepelev et al., 2015). The current study is the ﬁrst study that exam-
ined DBalP MN induction and mutagenicity following a sub-chronic
oral exposure, and the ﬁrst report of its mutagenicity in glandular stom-
ach, small intestine, and liver. Interestingly, DBalP has been demonstrat-
ed to be much more carcinogenic than BaP in animal models, and
perhaps the most carcinogenic of all PAHs tested to date (Cavalieri
et al., 1991, Cavalieri et al., 2005, Chen et al., 2013, Higginbotham
et al., 1993). Surprisingly, there are noprevious reports of TGRorMN re-
sults for BbF and BkF.
In our study, DBahA failed to elicit a positive TGR response for bone
marrow, yet it was positive in theMN assay. The only previous report of
TGR assay results for DBahA, which was published by our group and in-
corporated into the analyses presented herein, showed a positive re-
sponse in liver (Malik et al., 2013). Previous publications examining
DBahA genetic toxicity reported positive results formicronucleus induc-
tion in skin, bone marrow, spleen, and lung (Nishikawa et al., 2005,
Whong et al., 1994, Zhong et al., 1995); however the current study ap-
pears to be the ﬁrst to demonstrate a positive MN response in blood.
The results obtained indicate that INDENO, BaA, and BghiPwere neg-
ative in the MN assay. INDENO elicited a positive response in the TGR
assay for all tissues examined, whereas BaA was positive in the TGR
assay in all tissues except lung, and BghiP only elicited a positive TGR re-
sponse in small intestine and lung. There are no previous reports of TGR
results for any of these three compounds. In addition, to our knowledge
there are no reports in the literature regarding the ability of INDENO or
BghiP to induce MN in vitro or in vivo; however, several studies have
documented that BaA induces MN in skin, bone marrow, spleen, and
lung (Nishikawa et al., 2005, Whong et al., 1994, Zhong et al., 1995).
CHRY elicited positive TGR results for small intestine and lung only,
and was negative in the MN assay. Only one study has previously re-
ported positive TGR assay results for CHRY. Following an i.p. exposure
of Muta™Mouse, signiﬁcant elevations in lacZ mutant frequencies
were observed in liver, spleen, lung, kidney, bone marrow, and colon
(Yamada et al., 2005). Our study did not observe positive results in
liver or bone marrow; however, the Yamada et al. (2005) study used
an i.p. administration, which would contribute to elevated, direct expo-
sures of organs in the peritoneum (e.g., liver). To our knowledge, theliterature only contains a single report of a CHRY-induced increase in
MN; He and Baker (1991) documented a signiﬁcant increase in hairless
mouse skin following topical administration (He and Baker, 1991).
However, a similar study by Nishikawa (2005) failed to detect an in-
crease in MN in the same species and tissue following topical treatment
(Nishikawa et al., 2005).
Small intestine was not only the most sensitive among the tissues
examined, but also displayed the largest induction of lacZ mutant fre-
quency (i.e., the most potent response). It has previously been demon-
strated that inducible levels of Cyp1a1 gene expression in the small
intestine are relatively high, which is not the case for most other tissues
(Choudhary et al., 2003, Renaud et al., 2011). In the epithelium of the GI
tract, maximum induction levels of CYP1A1 have been shown to be 3–
10 times greater than CYP1B1, which in turn, have been shown to be
3–10 times greater than CYP1A2 (Uno et al., 2008). Studies with
Cyp1a1/1a2/1b1 single, double, and triple knockout mice have
highlighted and clariﬁed the roles of these enzymes in metabolizing
BaP and distributing BaP-metabolites following oral exposures
(reviewed in Nebert, et al. 2013). Knocking out Cyp1a1 expression
results in increased expression of Cyp1b1, concomitant bioactivation of
BaP, and adenocarcinoma formation in the proximal small intestine. In
contrast, BaP treated Cyp1b1 knockout were healthy (Shi et al.,
2010b). The relatively high levels of inducible CYP1A1 appear to be es-
pecially important in the detoxiﬁcation of BaP in the GI tract, whereas
CYP1B1 is implicated in the conversion of BaP to DNA-damagingmetab-
olites (Nebert, et al. 2013). Following an oral exposure, compounds such
as PAHs are absorbed from the small intestine and transported to the
liver, where they undergo oxidative metabolism. This metabolism
contributes to clearance of the parent compound, but also in the forma-
tion of DNA adducts and mutations in the liver itself. Additionally, as
PAH metabolites have been previously demonstrated to undergo
enterohepatic circulation, the small intestine would likely be re-
exposed to reactive metabolites, and this process would contribute to
increased levels of DNA damage that can, in turn, contribute to an in-
creased frequency of mutations (Miller and Ramos, 2001, Ramesh
et al., 2004). The combination of in situmetabolism in the small intes-
tine, coupled with re-exposure to reactive metabolites produced in the
liver and thehighmitotic index of the epithelial lining of the small intes-
tine, likely led to the high levels of transgene mutations.
Although the liver is the major site of PAH metabolism, both CHRY
and BghiP failed to induce signiﬁcant increases in lacZ mutations in
this tissue. Liver cells generally have a much lower mitotic index than
parenchymal cells in the other examined tissues (Edwards and Klein,
1961, White et al., provisionally accepted); therefore, for less potent
chemicals, a 28-day exposure regime with a 3-day sampling time may
not be sufﬁcient to allow for conversion of DNA damage to lacZmuta-
tions. Both CHRY and BghiP are relatively weak mutagens/carcinogens,
with BghiP being classiﬁed as IARC Group 3, and CHRY being recently
upgraded from Group 3 to 2B. If slowly proliferating tissues such as
liver are deemed to be of particular importance, the OECD protocol for
TGR assays indicates that a longer sampling time (e.g., 28-days post-
exposure) may be more appropriate (OECD, 2011).
The lacZmutagenic potency values for glandular stomachwere pen-
ultimate with a sensitivity of 78%. For an oral exposure the stomach is
the ﬁrst site-of-contact tissue, and although the metabolic capacity of
stomach epithelium is low in comparison with liver, the magnitude of
the response highlights the importance of examining tissues deemed
relevant to the exposure route. Only CHRY and BghiP, two of the
weakest PAHs examined, failed to elicit a positive response in this tissue.
The fact that lacZmutagenic activities were observed across all 5 tis-
sues, including remote tissues such as bonemarrow and lung, indicates
that several PAHs are capable of being metabolized and converted into
DNA-reactive substances at remote tissues in situ, or alternatively, that
the active metabolites are being systemically distributed. Lung was the
second most sensitive tissue for the TGR assay, returning a positive re-
sult for all compounds except BaA. Both Cyp1a1 and Cyp1b1 are highly
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Renaud et al., 2011); thus, lung has the ability to carry out in situ conver-
sion of PAHs to reactive diol-epoxides that would form bulky adducts.
This also appears to be the case for DBahA, CHRY, and BghiP, which
failed to elicit positive lacZ results in bone marrow, but elicited positive
results for lung. The negative BaA result for lung is troubling since BaA-
DNA adductswere detected in this tissue; however, due to the relatively
lowmitotic index of most lung parenchymal cells, DNA replication may
not be sufﬁcient to ﬁx a detectable level of mutations during the expo-
sure and sampling period employed here (White et al., provisionally
accepted).
In this study, bonemarrowwas the least sensitive tissue for the TGR
assay, and the lowest potency lacZ responses were also observed in
bone marrow, with DBahA, CHRY, and BghiP failing to elicit positive re-
sponses. Additionally, CHRY, BaA, INDENO, and BghiPwere unable to in-
duce MN in peripheral blood. The negative lacZ mutation and MN
responses in haematopoietic tissue from CHRY- and BghiP-exposed an-
imalsmay be the result of insufﬁcient exposure of the target tissue to re-
active metabolites. This is likely due to the lack of sufﬁcient distribution
of the parent compound to bone marrow and/or peripheral blood via
systemic circulation. As mentioned, following an oral exposure, induc-
tion of GI tract Cyp1a1 appears to be especially important for the detox-
iﬁcation of BaP, and this likely holds true for several PAHs. Thus,
following an oral exposure to PAHs that are effective AhR agonists, up-
regulation of Cyp1a1 expression in the GI tract/liver will contribute to
enhanced clearance, leaving little parent compound for systemic
distribution to bone marrow where reactive metabolites can be gener-
ated in situ via catalysis by isozymes such as CYP1B1. This supposition
is supported by the aforementioned knock-out studies that showed in-
creased damage at peripheral tissues if Cyp1a1 expression is knocked
out either globally or in the GI tract itself; moreover, the effect is re-
versed by also knocking out Cyp1b1 (Shi et al., 2010a, Uno et al.,
2006). However, it should be emphasized that the PAHs examined are
not equipotent AhR agonists. In this study, BaP and DBalP induced the
most potent lacZ and MN responses in bone marrow/blood, and inter-
estingly, BaP is a relatively poor AhR agonist in comparison to most of
the other PAHs examined. Furthermore, it is not clear whether DBalP
is an AhR ligand at all (Machala et al., 2001, Ziccardi et al., 2002), and
if it is not, one would not expect induction of Cyp1a1 expression in the
GI tract, leaving more parent compound available to be metabolized in
bone marrow by the constitutively expressed Cyp1b1. This deduction
is supported by our previousDBalP studywherewe observed signiﬁcant
bone marrow cytotoxicity that resulted in a substantial decrease in the
percentage of circulating RETs following a 3-day exposure (Chepelev
et al., 2015). In contrast to the aforementioned toxicokinetic processes
that likely modify the in vivo responses to BaP and DBalP, effective
AhR agonism, which has been observed for BkF, DBahA, and INDENO
(Ziccardi et al., 2002), and upregulation of Cyp1a1 expression in the GI
tract, would likely contribute to weak or negative bone marrow re-
sponses. Indeed, this is what was observed.
The results obtained failed to show a detectable increase in DNA ad-
ducts in bone marrow from CHRY-, BghiP-, and INDENO-treated ani-
mals, which supports the lack of exposure of haematopoietic tissue to
reactive metabolites. However, a signiﬁcant increase in adduct forma-
tion in the bone marrow of BaA-treated animals indicates that circula-
tion of this compound did occur, and that the bone marrow was
exposed to reactive, DNA-damaging metabolites. This is conﬁrmed by
the positive lacZ mutagenicity response in bone marrow. Therefore,
the aforementioned negative MN results may result from the inability
of the mutagenic metabolites to produce chromosome breaks and MN.
MN are produced during nuclear division when whole chromosome
or acentric chromosome or chromatid fragments lag behind at ana-
phase. This can result from mis-repair (or lack of repair) of double-
strand breaks, or simultaneous excision repair of damaged or incorrect
bases on opposite strands (Fenech et al., 2011). PAHs do not primarily
cause double strand breaks, but rather exert their mutagenic effect viaformation of bulky adducts that are repaired via nucleotide excision re-
pair. Although it has been well documented that several PAHs (i.e., BaP,
DBahA) are capable of inducing MN (Zhong et al., 1995), it is possible
that not all PAHs are capable of causing double strand breaks that con-
tribute to MN formation.
DBahAwas oneof the 3 compounds that failed to elicit a positive lacZ
mutagenicity response in the bonemarrow. As already noted, lack of re-
sponses for known mutagenic carcinogens are potentially indicative of
ineffective target tissue exposure. However, for DBahA, a positive re-
sponse in bone marrow was obtained for the adduct frequency and
MN endpoints, indicating that the haematopoietic tissue was exposed
to reactive metabolites. However, the tissue levels of reactive metabo-
lites were likely not sufﬁcient to overwhelm damage repair processes
that would inhibit the establishment of mutations. Alternatively, it is
possible that the positive MN response for DBahA resulted from a sec-
ondary metabolite (e.g., reactive oxygen) that did not contribute to
the formation of mutations in the bone marrow. It has previously been
shown that an alternatemetabolic pathway via dihydrodiol dehydroge-
nase leads to the auto-oxidation of PAH metabolites to o-quinones,
which can undergo redox cycling that generates DNA-damaging ROS
and depurinating adducts (IARC, 2014, Miller and Ramos, 2001,
Penning et al., 1996, Smithgall et al., 1988).
The haematopoietic tissue results for INDENO are interesting since
adducts were not detected in bone marrow, and the MN assay result
was negative; however, we did observe a signiﬁcant increase in lacZ
mutations. Given the lack of bulky adducts, it is unlikely that the reac-
tivemetabolites are reaching the bonemarrow via systemic circulation.
A likely alternative cause of the observed lacZmutations, which would
not contribute to the formation of bulky INDENO-DNA adducts, is reac-
tive oxygen species (ROS) generated via the aforementioned o-quinone
pathway. Some PAHs, especially those with higher molecular weights
(e.g., INDENO), have been found to have greater redox activity that
can readily lead to ROS formation and oxidative DNA damage, among
other types of cellular injury (Jeng et al., 2011). Oxidative DNA damage
cannot be detected using the 32P-postlabelling methodology employed
in this study.
Several published studies have previously examined the in vivo ge-
netic toxicity of PAHs; however, the vast majority of these studies
assessed responses following i.p. administrations (i.e., no ﬁrst-pass me-
tabolism), which is generally not considered useful for regulatory deci-
sions thatmust consider themost likely route of receptor exposure. The
most common route of human PAH exposure is oral, followed by inha-
lation, and dermal. This study is the ﬁrst to employ an identical oral ex-
posure regime to simultaneously evaluate induction of transgene (lacZ)
mutations in various tissues and MN formation in peripheral blood fol-
lowing TGR exposures to 9 PAHs. This type of study is essential to criti-
cally evaluate the utility of TGR tools for regulatory genetic toxicity
assessment (i.e., assay sensitivity), to compare and contrast TGR results
across various tissues (OECD #488), and perhaps more importantly, to
benchmark TGR responses against the MN endpoint in peripheral
blood (OECD #474).
As noted, the current study concurrently examined induced lacZmu-
tations in 5 tissues, and the frequency of MN in RETs and NCEs, follow-
ing sub-chronic oral administration of 9 PAHs. The evaluation of both of
these endpoints was conducted in accordance with the protocols for
dosing and sample collection recommended in the relevant OECD
guidelines (i.e., OECD #474 & 488), and this work demonstrates that
the two complementary endpoints can be integrated into a single sub-
chronic study, thus providing concurrent assessment of mutation and
chromosome damage. Although the study was restricted to a single
compound class (i.e., PAHs), the results nonetheless underscore the util-
ity of simultaneous genetic toxicity assessment in multiple tissues
across multiple endpoints (i.e., mutation and cytogenetic damage).
Additional research is required to determinewhether the observed sen-
sitivity of the TGR mutagenicity endpoint is generally applicable, and
additionally, whether speciﬁcity is equally suitable. Interestingly,
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the ability of the Muta™Mouse lacZmutagenicity assay to return posi-
tive results for a wide range of genotoxic compounds, including carcin-
ogens that failed to elicit positive responses in the in vivoMN assay. For
example, Oxazepam (7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-
benzodiazepin-2-one), a carcinogen that failed to elicit MN in vitro
and in vivo, was shown to elicit a positive response in a TGRmutagenic-
ity assay (Lambert et al., 2009). Indeed, we are currently expanding this
type of analysis and employing the Muta™Mouse system to examine
the in vivo mutagenicity of carcinogens that failed to elicit positive
clastogenicity responses in vivo (i.e., false negatives).
Overall, with respect to the tissues examined in this study, the
Muta™Mouse lacZmutagenicity assay was more sensitive (i.e., correct
identiﬁcation of mutagenic carcinogens) than the peripheral blood
MN assay; moreover, for the Muta™Mouse endpoint, bone marrow
was the least sensitive of the tissues examined. Small intestine, a site-
of-contact tissue for oral exposure, was the most sensitive tissue, with
the responses therein constituting the largest observed increases inmu-
tant frequency for the PAHs examined. The results of this study call into
question the reliability of only examining tissues that are remote from
the site of contact (e.g., blood or bone marrow) when assessing the
genotoxic hazard of substances for which the primary route of exposure
is oral. Moreover, following up an in vitro positive result for mutation
with an in vivo clastogenicity assay is not necessarily effective, and
may even lead to the generation of in vivo false negatives. This is partic-
ularly important for carcinogens (e.g., PAHs) that must bemetabolically
converted into DNA-reactivemetabolites, since the reactivemetabolites
may not be systemically distributed and/or may only be generated in
situ in remote tissues (e.g., bone marrow). As noted, phenomena such
as AhR agonism in site of contact and remote tissues can control the na-
ture of the tissue exposure (e.g., type and level of reactive metabolites),
and the effects manifested therein that are indicative of sensitivity.
5. Conclusion
It is evident from the results presented that a dynamic interplay be-
tween several phenomena govern tissue-speciﬁc induction of genetic
toxicity endpoints including DNA damage (i.e., adduct frequency), mu-
tagenicity (i.e., lacZ transgene mutations), and clastogenicity (i.e., MN).
Speciﬁcally, genetic damage in a target tissue appears to be controlled
by dynamic processes that regulate (i) absorption, tissue-speciﬁc me-
tabolism and systemic distribution of bothmetabolites and parent com-
pounds, (ii) tissue-speciﬁc damage response and DNA repair capacity,
and (iii) tissue-speciﬁc cellular proliferation.
The results presented clearly demonstrate the utility of the Muta™-
Mouse TGR assay for reliable in vivo mutagenicity assessment of
suspected carcinogens with a mutagenic mode of action; in particular,
for substances that require metabolic conversion to DNA-reactive me-
tabolites (i.e., PAHs). Furthermore, the low sensitivity of the peripheral
blood MN and the lacZ mutagenicity responses in bone marrow
(i.e., limited ability to identify mutagenic carcinogens) highlights the
need to examine site-of-contact tissues in addition to haematopoietic
tissues, particularly for weak mutagens. Simultaneous enumeration of
induced lacZmutations in several tissues and micronuclei in peripheral
blood, comprises complementary components of a highly sensitive sys-
tem for the detection of mutagenic carcinogens, and we are currently
extending the type of analyses presented herein to encompass priori-
tized environmental matrices contaminated with complex mixtures of
combustion-derived PAHs (e.g., contaminated soil, coal-tar amended
consumer products).
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